Home > Compound List > Product Information
Risedronate_Molecular_structure_CAS_105462-24-6)
Click picture or here to close

Risedronate

Catalog No. DB00884 Name DrugBank
CAS Number 105462-24-6 Website http://www.ualberta.ca/
M. F. C7H11NO7P2 Telephone (780) 492-3111
M. W. 283.112262 Fax (780) 492-1071
Purity Email david.wishart@ualberta.ca
Storage Chembase ID: 762

SYNONYMS

IUPAC name
[1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl]phosphonic acid
IUPAC Traditional name
risedronate
Brand Name
Actonel
Actonel 150
Benet
Synonyms
risedronate
Risedronate sodium
Risedronic acid
NE-58095

DATABASE IDS

CAS Number 105462-24-6
PubChem CID 5245
PubChem SID 46507526

PROPERTIES

Hydrophobicity(logP) -3.6

DETAILS

Description (English)
Item Information
Drug Groups approved; investigational
Description Risedronate is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis, and treat Paget's disease of bone.
Indication For the treatment of Paget's disease of the bone (osteitis deformans), postmenopausal and glucocorticoid-induced osteoporosis
Pharmacology Risedronate is a pyridinyl bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism and is indicated for the treatment and prevention of osteoporosis in postmenopausal women.
Toxicity Side effects include abdominal pain, anxiety, back pain, belching, bladder irritation, bone disorders and pain, bronchitis, bursitis, cataracts, chest pain, colitis, constipation, depression, diarrhea, difficulty breathing, dizziness, dry eyes, eye infection, flu-like symptoms, gas, headache, high blood pressure, infection, insomnia, itching, joint disorders and pain, leg cramps, muscle pain, muscle weakness, nausea, neck pain, nerve pain, pain, pneumonia, rash, ringing in ears, sinus problems, sore throat, stomach bleeding, stuffy or runny nose, swelling, tendon problems, tumor, ulcers, urinary tract infection, vertigo, vision problems, and weakness.
Affected Organisms
Humans and other mammals
Biotransformation No evidence found for metabolization of risedronate in humans or mammals
Absorption Rapid absorption (~1 hr) after an oral dose, occurs throughout the upper gastrointestinal tract
Half Life 1.5 hours
Protein Binding ~24%
Elimination Risedronate is excreted unchanged primarily via the kidney. Insignificant amounts (<0.1% of intravenous dose) of drug are excreted in the bile in rats.
Distribution * 13.8 L/kg
Clearance * 122 mL/min
* 73 mL/min [osteopenic postmenopausal women]
External Links
Wikipedia
RxList
PDRhealth
Drugs.com

REFERENCES